Bladder transitional cell carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:58:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder transitional cell carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer to Reduce Need for Second Surgery https://clinicaltrials.eu/trial/study-on-hexaminolevulinate-for-patients-with-non-muscle-invasive-bladder-cancer-to-reduce-need-for-second-surgery/ Wed, 29 Apr 2026 14:56:53 +0000 https://clinicaltrials.eu/trial/study-on-hexaminolevulinate-for-patients-with-non-muscle-invasive-bladder-cancer-to-reduce-need-for-second-surgery/ This clinical trial is focused on studying non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has not spread into the muscle layer of the bladder. The study is comparing two different surgical methods for removing bladder tumors. One method uses a special technique called Photodynamic Trans-urethral Resection of Bladder Tumors (PDD-TURBT), which involves using a light-sensitive drug called Hexvix (hexaminolevulinate) to help doctors see and remove the cancer more clearly. The other method is the conventional approach using white light during surgery, followed by a second surgery if needed.

The purpose of the study is to see if the PDD-TURBT method can help avoid the need for a second surgery without increasing the risk of cancer coming back. Participants in the study will be randomly assigned to one of the two surgical methods. After the surgery, they will be monitored for any signs of cancer returning, with follow-up checks scheduled over several months. The study aims to provide evidence on whether the new method can be as effective as the standard approach while potentially reducing the need for additional surgeries.

Throughout the study, researchers will compare the outcomes of patients who undergo the PDD-TURBT method with those who have the conventional surgery. They will look at how often the cancer returns, the time it takes for any recurrence, and the overall health and quality of life of the participants. The study will also assess the costs associated with each method to determine if the new approach could be more cost-effective in the long run. The findings from this study could help improve treatment guidelines for patients with NMIBC.

]]>